BioCentury
ARTICLE | Company News

Link gets China rights to 4SC cancer candidate

June 1, 2016 1:19 AM UTC

4SC AG (Xetra:VSC) granted Link Health Group (Guangzhou, China) exclusive rights to oncology candidate 4SC-205 in China, Hong Kong, Taiwan and Macau. Link Health will be responsible for clinical development of the oral inhibitor of kinesin spindle protein ( KSP; Eg5; TRIP5), which has completed a Phase I study in solid tumors.

4SC is eligible to receive an upfront payment and milestones totaling EUR 76 million ($84.5 million), plus double-digit royalties. 4SC said it is seeking other partners for the candidate, and may use clinical data generated by Link Health to pursue approvals elsewhere. ...